| Ms Cynthia Marie Armour, RPH | |
|
2050 Government Blvd, Walgreens #7609, Mobile, AL 36606 | |
| (251) 476-1825 | |
| (251) 476-7128 |
| Full Name | Ms Cynthia Marie Armour |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2050 Government Blvd, Mobile, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033198114 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 14330 (Alabama) | Primary |
| 183500000X | Pharmacist | 26328 (Texas) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Cynthia Marie Armour, RPH Po Box 17, Dauphin Island, AL 36528-0017 Ph: (251) 510-0606 | Ms Cynthia Marie Armour, RPH 2050 Government Blvd, Walgreens #7609, Mobile, AL 36606 Ph: (251) 476-1825 |
News Archive
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.
TechPrecision Corporation (OTC Bulletin Board: TPCS) ("TechPrecision", or "the Company"), a leading manufacturer of large-scale, high-precision machined metal fabrications with customers in the alternative energy, medical, nuclear, defense, aerospace and other commercial industries, today released the following open letter to shareholders reviewing the highlights of 2009 and providing an overview of the Company's strategic plan and outlook for 2010.
Randomized phase III studies should be designed to find out whether a new drug or treatment makes a meaningful difference in patients' survival or quality of life, according to a commentary published online December 3rd in The Journal of the National Cancer Institute.
New data presented at the American Thoracic Society's 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.
A new study in the American Journal of Preventive Medicine, published by Elsevier, reports valuable new grip strength metrics that provide healthcare practitioners with an easy-to-perform, time-efficient screening tool for type 2 diabetes.
› Verified 9 days ago
Dr. Wilfred Arcard Brown, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3948 Airport Blvd, Mobile, AL 36608 Phone: 251-345-3394 | |
Chidiya Ohiagu, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1303 Dr Martin L King Jr Ave, Mobile, AL 36603 Phone: 251-432-4117 | |
Darren P Billiot, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6575 Airport Blvd, Mobile, AL 36608 Phone: 251-370-9848 | |
Eric Donaldson Reeves, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4628 Airport Blvd, Mobile, AL 36608 Phone: 251-341-5749 | |
Mr. Chuck P Whisonant, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1504 Spring Hill Ave, Mobile, AL 36604 Phone: 251-219-3754 | |
Ms. Angela F. Amos, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 251 N Bayou St, Mobile, AL 36603 Phone: 251-690-8817 | |
Dr. Raymond Lorenz, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2400 Gordon Smith Dr, Mobile, AL 36617 Phone: 251-450-1388 |